Chelsea Therapeutics tumbles as investors digest briefing docs

Briefing docs are out for next week's Northera (CHTP) Ad Com.

FDA staff list five arguments in favor of approval and seven against approval.

"The primary reason not to recommend approval is the lack of sufficient evidence of efficacy," the documents say.

Full documents

CHTP -21% premarket

From other sites
Comments (1)
  • hneumann
    , contributor
    Comments (630) | Send Message
    Where on the FDA website todays Northera review can be found ?
    10 Jan 2014, 02:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs